|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM038879263 |
003 |
DE-627 |
005 |
20231221143942.0 |
007 |
tu |
008 |
231221s1985 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0130.xml
|
035 |
|
|
|a (DE-627)NLM038879263
|
035 |
|
|
|a (NLM)3906673
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Roussan, M
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy
|
264 |
|
1 |
|c 1985
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 30.12.1985
|
500 |
|
|
|a Date Revised 21.11.2013
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Baclofen (25 to 60 mg per day) and diazepam (10 to 40 mg per day) were evaluated for spasticity reduction in a double-blind, crossover study in 13 patients over a period of 19 weeks. Both drugs produced overall improvement and there was no significant difference in preference for one or other treatment. Side-effects, especially excessive daytime sedation, were more common in the diazepam group. In a companion baclofen long-term study, 18 spastic patients were treated with baclofen for an average of 4 years. Baclofen discontinuation in this group resulted in a worsening of spastic signs and symptoms in 16 patients, with no evidence of drug tolerance even after many years of baclofen therapy
|
650 |
|
4 |
|a Clinical Trial
|
650 |
|
4 |
|a Comparative Study
|
650 |
|
4 |
|a Controlled Clinical Trial
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Randomized Controlled Trial
|
650 |
|
4 |
|a Research Support, U.S. Gov't, Non-P.H.S.
|
650 |
|
7 |
|a Baclofen
|2 NLM
|
650 |
|
7 |
|a H789N3FKE8
|2 NLM
|
650 |
|
7 |
|a Diazepam
|2 NLM
|
650 |
|
7 |
|a Q3JTX2Q7TU
|2 NLM
|
700 |
1 |
|
|a Terrence, C
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fromm, G
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 4(1985), 5 vom: 23., Seite 278-84
|w (DE-627)NLM023961570
|
773 |
1 |
8 |
|g volume:4
|g year:1985
|g number:5
|g day:23
|g pages:278-84
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_72
|
912 |
|
|
|a GBV_ILN_120
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 4
|j 1985
|e 5
|b 23
|h 278-84
|